Ipsen SA, of Paris, and BioMérieux SA, of Marcy l'Etoile, France, said they will collaborate to leverage Ipsen's portfolio of compounds and BioMérieux's diagnostic tests and identify programs that would benefit from the co-development of a therapeutic and a companion diagnostic test, notably in the prevention and treatment of prostate and breast cancers, neuro-endocrine tumors and pituitary tumors.